N.E.W. Advisory Services’s BridgeBio Pharma BBIO Stock Holding History

N.E.W. Advisory Services’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Hold	20	–	–	﹤0.01%	878
2026 Q1	$1.49K	Hold	20	–	–	﹤0.01%	844
2025 Q4	$1.53K	Hold	20	–	–	﹤0.01%	821
2025 Q3	$1.04K	Buy	+20	New	+$975	﹤0.01%	793

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

N.E.W. Advisory Services's BBIO Position: Q2 2026 in Review

N.E.W. Advisory Services held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 20 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #878.

N.E.W. Advisory Services first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.53K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

N.E.W. Advisory Services held 20 shares of BridgeBio Pharma worth $1.49K as of Q2 2026.
N.E.W. Advisory Services left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q2 2026, its #878 holding.
N.E.W. Advisory Services first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
N.E.W. Advisory Services's BridgeBio Pharma position peaked at $1.53K in Q4 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on N.E.W. Advisory Services's 13F filing for Q2 2026, filed 6 Aug 2026.